Conversion From Brand to Generic Tacrolimus in High Risk Transplant Recipients
NCT ID: NCT02014103
Last Updated: 2024-10-15
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
71 participants
INTERVENTIONAL
2015-03-31
2015-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pharmacokinetic Studies of Tacrolimus in Transplant Patients
NCT01889758
Pharmacokinetics of Generic to Brand Tacrolimus in Stable Renal Transplant Patients
NCT01256294
A Study to Compare the Conversion to Prograf® (Tacrolimus) to the Continuation of Cyclosporine in Patients at Risk for Chronic Renal Allograft Failure
NCT00510913
Pre-transplant Assessment of Tacrolimus Blood Level Concentration, as a Predictor of Tacrolimus Dose Requirements After Kidney Transplantation
NCT00297310
A Study to Assess the Pharmacokinetics of a Modified-release Tacrolimus Based Immunosuppression Regimen in Stable Kidney Transplant Patients
NCT00282568
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Sequence 1
Patients will be randomized to a sequence of administration of the various 6 tacrolimus formulations. Sequence 1: Formulation Sandoz, Panacea, Accord, Mylan, Dr. Reddy's, Astellas
Patients will be receiving the same tacrolimus dose identified at baseline for each formulation.
Prograf
Administration of each formulation will be determined by sequence.
Tacrolimus, Sandoz
Administration of each formulation will be determined by sequence.
Tacrolimus, Reddy Laboratory
Administration of each formulation will be determined by sequence.
Tacrolimus, Mylan
Administration of each formulation will be determined by sequence.
Tacrolimus, Accord
Administration of each formulation will be determined by sequence.
Tacrolimus, Pancea Biotech Limited
Administration of each formulation will be determined by sequence.
Sequence 2
Patients will be randomized to a sequence of administration of the various 6 tacrolimus formulations. Sequence 2: Formulation Accord, Sandoz, Dr. Reddy's, Panacea, Astellas, Mylan
Patients will be receiving the same tacrolimus dose identified at baseline for each formulation.
Prograf
Administration of each formulation will be determined by sequence.
Tacrolimus, Sandoz
Administration of each formulation will be determined by sequence.
Tacrolimus, Reddy Laboratory
Administration of each formulation will be determined by sequence.
Tacrolimus, Mylan
Administration of each formulation will be determined by sequence.
Tacrolimus, Accord
Administration of each formulation will be determined by sequence.
Tacrolimus, Pancea Biotech Limited
Administration of each formulation will be determined by sequence.
Sequence 3
Patients will be randomized to a sequence of administration of the various 6 tacrolimus formulations. Sequence 3: Formulation Dr. Reddys, Accord, Astellas, Sandoz, Mylan, Panacea
Patients will be receiving the same tacrolimus dose identified at baseline for each formulation.
Prograf
Administration of each formulation will be determined by sequence.
Tacrolimus, Sandoz
Administration of each formulation will be determined by sequence.
Tacrolimus, Reddy Laboratory
Administration of each formulation will be determined by sequence.
Tacrolimus, Mylan
Administration of each formulation will be determined by sequence.
Tacrolimus, Accord
Administration of each formulation will be determined by sequence.
Tacrolimus, Pancea Biotech Limited
Administration of each formulation will be determined by sequence.
Sequence 4
Patients will be randomized to a sequence of administration of the various 6 tacrolimus formulations. Sequence 4: Formulation Astellas, Dr. Reddy's, Mylan, Accord, Panacea, Sandoz
Patients will be receiving the same tacrolimus dose identified at baseline for each formulation.
Prograf
Administration of each formulation will be determined by sequence.
Tacrolimus, Sandoz
Administration of each formulation will be determined by sequence.
Tacrolimus, Reddy Laboratory
Administration of each formulation will be determined by sequence.
Tacrolimus, Mylan
Administration of each formulation will be determined by sequence.
Tacrolimus, Accord
Administration of each formulation will be determined by sequence.
Tacrolimus, Pancea Biotech Limited
Administration of each formulation will be determined by sequence.
Sequence 5
Patients will be randomized to a sequence of administration of the various 6 tacrolimus formulations. Sequence 5: Formulation Mylan, Astellas, Panacea, Dr. Reddy's, Sandoz, Accord
Patients will be receiving the same tacrolimus dose identified at baseline for each formulation.
Prograf
Administration of each formulation will be determined by sequence.
Tacrolimus, Sandoz
Administration of each formulation will be determined by sequence.
Tacrolimus, Reddy Laboratory
Administration of each formulation will be determined by sequence.
Tacrolimus, Mylan
Administration of each formulation will be determined by sequence.
Tacrolimus, Accord
Administration of each formulation will be determined by sequence.
Tacrolimus, Pancea Biotech Limited
Administration of each formulation will be determined by sequence.
Sequence 6
Patients will be randomized to a sequence of administration of the various 6 tacrolimus formulations. Sequence 6: Formulation Panacea, Mylan, Sandoz, Astellas, Accord, Dr. Reddy's
Patients will be receiving the same tacrolimus dose identified at baseline for each formulation.
Prograf
Administration of each formulation will be determined by sequence.
Tacrolimus, Sandoz
Administration of each formulation will be determined by sequence.
Tacrolimus, Reddy Laboratory
Administration of each formulation will be determined by sequence.
Tacrolimus, Mylan
Administration of each formulation will be determined by sequence.
Tacrolimus, Accord
Administration of each formulation will be determined by sequence.
Tacrolimus, Pancea Biotech Limited
Administration of each formulation will be determined by sequence.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Prograf
Administration of each formulation will be determined by sequence.
Tacrolimus, Sandoz
Administration of each formulation will be determined by sequence.
Tacrolimus, Reddy Laboratory
Administration of each formulation will be determined by sequence.
Tacrolimus, Mylan
Administration of each formulation will be determined by sequence.
Tacrolimus, Accord
Administration of each formulation will be determined by sequence.
Tacrolimus, Pancea Biotech Limited
Administration of each formulation will be determined by sequence.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Able to participate and willing to give written informed consent/ assent/ consent by parent or legal guardian and to comply with the study visits and restrictions.
3. Subject who has received a primary or secondary transplant.
4. Subject who is at least 6 months post-transplant and on a stable dose of tacrolimus as defined by physician, one tacrolimus trough level within the physician defined target range within past 6 months and one additional trough level during the screening period within 30% of the physician defined target range.
5. BMI less than or equal to 40.
Exclusion Criteria
2. Subjects who require dialysis within 6 months prior to study entry
3. Recipients of multiple organ transplants
4. Subjects who have tested positive for HBsAG or HIV, or who are recipients of organ from donors who are known to be HBsAG or HIV positive. Virology screening at the time of transplant.
5. HepC positive subjects with liver biopsy proven recurrent disease considered relevant by physician oversight.
6. Subjects with any severe medical condition requiring acute or chronic treatment that in the investigator's opinion would interfere with study participation
7. History of malignancy, treated or untreated, with the past 2 years with the exception of carcinoma in situ or excised basal cell carcinoma, or hepatocellular carcinoma prior to transplant.
8. GFR ≤ 35 ml/min measured as estimated using the MDRD4 formula
9. Subjects with AST, ALT, total bilirubin ≥ 3 X ULN or other evidence of severe liver disease
10. Subjects with white blood cell (WBC) count ≤2,000/ mm3 or with thrombocytopenia (platelet count ≤ 75,000/ mm3), with an absolute neutrophil count of ≤ 1,500/ mm3 or hemoglobin \<8g/dL)
11. Subjects with clinically significant infections, requiring therapy, which, in the investigator's opinion, would interfere with the objectives of the study
12. Other mental or physical conditions which in the investigator's opinion, are considered clinically significant
13. Presence of intractable immunosuppressant complications or side effects resulting in dose adjustment of tacrolimus
14. Subjects who have been exposed to an investigational therapy within 30 days prior to enrollment or 5 half-lives of the investigational product, whichever is greater.
15. An anticipated change in the immunosuppressive regimen during subject participation other than that required by the protocol
16. Subject with severe GI disturbance or diarrhea which could interfere with tacrolimus absorption
17. Severe diabetic gastroparesis
18. Initiation of any medications that could interfere with tacrolimus blood levels, including OTC medications, herbal supplements, grapefruit or grapefruit juice.
19. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive BhCG laboratory test (\> 5 mIU/mL)
20. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are: 1) women whose career, lifestyle, or sexual orientation precludes intercourse with a male partner; 2)women whose partners have been sterilized by vasectomy or 3)using a highly effective method of birth control (i.e. one that results in a less than 1% per year failure rate when used consistently and correctly, such as implants, injectables, combined oral contraceptives, and some intrauterine devices (IUDs); periodic abstinence (e.g. calendar, ovulation, symptothermal, post-ovulation methods) is not acceptable.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Colorado, Denver
OTHER
Children's Hospital Medical Center, Cincinnati
OTHER
University of Cincinnati
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Rita Alloway
Research Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Rita R Alloway, PharmD
Role: PRINCIPAL_INVESTIGATOR
University of Cincinnati
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Cincinnati Medical Center
Cincinnati, Ohio, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FDA
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
13-223-SOL-00102
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.